AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 28341300 — intervention group
Group type: EXPERIMENTAL
Intervention: Intraperitoneal bortezomib and carboplatin (AUC 4 or 5) every 21 days for 6 cycles
Number of subjects: 33
Study 28341306 — intervention group
Group type: EXPERIMENTAL
Intervention: High-frequency QRS (HFQRS) analysis
Number of subjects: 324
Study 28341306 — intervention group
Group type: COMPARATOR
Intervention: Conventional ECG diagnosis by treating physician
Number of subjects: 324
Study 28341306 — intervention group
Group type: COMPARATOR
Intervention: Conventional ECG diagnosis by expert cardiologist
Number of subjects: 324
Study 28341306 — intervention group
Group type: COMPARATOR
Intervention: Automated computer program for ECG diagnosis
Number of subjects: 324
Study 28341495 — intervention group
Group type: EXPERIMENTAL
Intervention: TMX-101 (200mg/50ml, 0.4%) administered intravesically for 6 weeks
Number of subjects: 12
Study 28341686 — intervention group
Group type: EXPERIMENTAL
Intervention: Brain MRI incidental findings (IF)
Number of subjects: 575
Study 28341686 — intervention group
Group type: EXPERIMENTAL
Intervention: Relevant white matter hyperintensities (WMH)
Number of subjects: 575
Study 28341686 — intervention group
Group type: EXPERIMENTAL
Intervention: Vascular abnormalities
Number of subjects: 575
Study 28341686 — intervention group
Group type: EXPERIMENTAL
Intervention: Cysts
Number of subjects: 575
Study 28341686 — intervention group
Group type: EXPERIMENTAL
Intervention: Brain volume loss
Number of subjects: 575
Study 28341686 — intervention group
Group type: EXPERIMENTAL
Intervention: Neoplastic brain findings
Number of subjects: 575
Study 28341686 — intervention group
Group type: EXPERIMENTAL
Intervention: Correlation between age and IF
Number of subjects: 575
Study 28341686 — intervention group
Group type: EXPERIMENTAL
Intervention: Brain atrophy
Number of subjects: 575
Study 28341957 — intervention group
Group type: EXPERIMENTAL
Intervention: pegylated liposomal doxorubicin 30 mg/m² plus lapatinib
Number of subjects: 11
Study 28342180 — intervention group
Group type: EXPERIMENTAL
Intervention: ART containing zidovudine
Number of subjects: 1166
Study 28342180 — intervention group
Group type: COMPARATOR
Intervention: ART containing tenofovir disoproxil
Number of subjects: 1166
Study 28342180 — intervention group
Group type: EXPERIMENTAL
Intervention: NNRTI-based ART (both zidovudine and tenofovir)
Number of subjects: 1166
Study 28342713 — intervention group
Group type: EXPERIMENTAL
Intervention: Laboratory score combining glucose, RDW, eGFR with hs-cTnT or hs-cTnI
Number of subjects: 1095
Study 28342713 — intervention group
Group type: COMPARATOR
Intervention: hs-cTn alone using the limit of detection (LoD)
Number of subjects: 1095
Study 28342989 — intervention group
Group type: EXPERIMENTAL
Intervention: DAA regimens
Number of subjects: 1600
Study 28343143 — intervention group
Group type: EXPERIMENTAL
Intervention: Rivaroxaban 20mg
Number of subjects: 20
Study 28343236 — intervention group
Group type: EXPERIMENTAL
Intervention: Chloride-limited fluid strategy (buffered salt solution and 20% albumin)
Number of subjects: 1136
Study 28343236 — intervention group
Group type: COMPARATOR
Intervention: Chloride-rich fluid strategy (0.9% saline and 4% albumin)
Number of subjects: 1136
Study 28343449 — intervention group
Group type: EXPERIMENTAL
Intervention: Severe iron loading with very low T2* of 5.0 ± 2.0 ms (iron concentration 8.5 ± 7.0 mg/g dw) and diffuse granular myocardial iron deposition.
Number of subjects: 10
Study 28343449 — intervention group
Group type: EXPERIMENTAL
Intervention: Interstitial fibrosis quantified by computer using picrosirius red (PSR) staining expressed as collagen volume fraction (CVF).
Number of subjects: 10
Study 28343449 — intervention group
Group type: EXPERIMENTAL
Intervention: Severe cardiac siderosis and heart failure.
Number of subjects: 10
Study 28343449 — intervention group
Group type: EXPERIMENTAL
Intervention: Replacement cardiac fibrosis.
Number of subjects: 10
Study 28343449 — intervention group
Group type: EXPERIMENTAL
Intervention: Minor interstitial fibrosis.
Number of subjects: 10
Study 28343763 — intervention group
Group type: EXPERIMENTAL
Intervention: Implantable cardiac monitors with remote monitoring capabilities (SMART-MI trial)
Number of subjects: 0
Study 28343763 — intervention group
Group type: EXPERIMENTAL
Intervention: Implantable cardioverter defibrillator (ICD) therapy (REFINE-ICD trial)
Number of subjects: 0
Study 28344643 — intervention group
Group type: EXPERIMENTAL
Intervention: TAU + GOLIAH (automated serious gaming platform, 4 sessions of 30 minutes per week at home and 1 session at hospital for 6 months)
Number of subjects: 14
Study 28344643 — intervention group
Group type: EXPERIMENTAL
Intervention: TAU + GOLIAH
Number of subjects: 14
Study 28344643 — intervention group
Group type: COMPARATOR
Intervention: TAU
Number of subjects: 14
Study 28344793 — intervention group
Group type: EXPERIMENTAL
Intervention: Colonoscopy
Number of subjects: 5722
Study 28344793 — intervention group
Group type: COMPARATOR
Intervention: Fecal Immunochemical Testing (FIT)
Number of subjects: 5722
Study 28344793 — intervention group
Group type: EXPERIMENTAL
Intervention: Colonoscopy (primary and work-up)
Number of subjects: 5722
Study 28345157 — intervention group
Group type: COMPARATOR
Intervention: 0.5 mg/day entecavir
Number of subjects: 275
Study 28345157 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.5 mg/day entecavir maleate
Number of subjects: 275
Study 28345539 — intervention group
Group type: EXPERIMENTAL
Intervention: Moderate hyperglycemia
Number of subjects: 0
Study 28345539 — intervention group
Group type: EXPERIMENTAL
Intervention: Severe hyperglycemia
Number of subjects: 0
Study 28345539 — intervention group
Group type: EXPERIMENTAL
Intervention: Hypoglycemia
Number of subjects: 0
Study 28345539 — intervention group
Group type: COMPARATOR
Intervention: Euglycemia
Number of subjects: 0
Study 28345951 — intervention group
Group type: EXPERIMENTAL
Intervention: Stereotactic Ablative Radiotherapy
Number of subjects: 0
Study 28346229 — intervention group
Group type: EXPERIMENTAL
Intervention: Autologous hematopoietic stem cell transplantation with gene-modified CD34+ cells (MND-ADA) after busulfan conditioning (90 mg/m2) and ERT cessation
Number of subjects: 10
Study 28346229 — intervention group
Group type: EXPERIMENTAL
Intervention: Autologous hematopoietic stem cell transplantation with gene-modified CD34+ cells (MND-ADA)
Number of subjects: 10
Study 28346714 — intervention group
Group type: EXPERIMENTAL
Intervention: ELISA (>0.35 μg/ml)
Number of subjects: 30
Study 28346714 — intervention group
Group type: EXPERIMENTAL
Intervention: OPA (>1:8)
Number of subjects: 30
Study 28346714 — intervention group
Group type: EXPERIMENTAL
Intervention: ELISA
Number of subjects: 30
Study 28346737 — intervention group
Group type: EXPERIMENTAL
Intervention: MRI
Number of subjects: 442
Study 28346737 — intervention group
Group type: EXPERIMENTAL
Intervention: CT
Number of subjects: 442
Study 28346737 — intervention group
Group type: EXPERIMENTAL
Intervention: CEUS
Number of subjects: 442
Study 28346737 — intervention group
Group type: EXPERIMENTAL
Intervention: MRI + CT
Number of subjects: 442
Study 28346737 — intervention group
Group type: EXPERIMENTAL
Intervention: CEUS as second imaging technique
Number of subjects: 442
Study 28346762 — intervention group
Group type: EXPERIMENTAL
Intervention: Chronic pain (CP)
Number of subjects: 144
Study 28346762 — intervention group
Group type: EXPERIMENTAL
Intervention: Persistent pain (PP)
Number of subjects: 144
Study 28346762 — intervention group
Group type: EXPERIMENTAL
Intervention: Preoperative pain and higher postoperative opioid requirement
Number of subjects: 144
Study 28346762 — intervention group
Group type: EXPERIMENTAL
Intervention: Childhood Anxiety Sensitivity Index
Number of subjects: 144
Study 28346762 — intervention group
Group type: EXPERIMENTAL
Intervention: Surgical duration
Number of subjects: 144
Study 28346762 — intervention group
Group type: EXPERIMENTAL
Intervention: Anxiety scores and catastrophizing for child and parent
Number of subjects: 144
Study 28346762 — intervention group
Group type: EXPERIMENTAL
Intervention: Pain trajectories
Number of subjects: 144
Study 28346762 — intervention group
Group type: EXPERIMENTAL
Intervention: Pain criteria
Number of subjects: 144
Study 28347290 — intervention group
Group type: EXPERIMENTAL
Intervention: Bevacizumab-based chemotherapy
Number of subjects: 122
Study 28347290 — intervention group
Group type: COMPARATOR
Intervention: Not applicable
Number of subjects: 122
Study 28347564 — intervention group
Group type: EXPERIMENTAL
Intervention: Walnuts (30 g/d)
Number of subjects: 94
Study 28347564 — intervention group
Group type: EXPERIMENTAL
Intervention: Pomegranate extract (450 mg/d)
Number of subjects: 94
Study 28347564 — intervention group
Group type: EXPERIMENTAL
Intervention: Nuts (15 g-walnuts, 7.5 g-hazelnuts and 7.5 g-almonds/d)
Number of subjects: 94
Study 28347564 — intervention group
Group type: EXPERIMENTAL
Intervention: Statin-treated MetS patients with UM-A
Number of subjects: 94
Study 28347564 — intervention group
Group type: EXPERIMENTAL
Intervention: MB patients
Number of subjects: 94
Study 28347734 — intervention group
Group type: EXPERIMENTAL
Intervention: Current asthma at age 8 years (n=37)
Number of subjects: 127
Study 28347734 — intervention group
Group type: EXPERIMENTAL
Intervention: Risk factors for current atopic asthma
Number of subjects: 127
Study 28347734 — intervention group
Group type: EXPERIMENTAL
Intervention: Risk factors for nonatopic asthma
Number of subjects: 127
Study 28347955 — intervention group
Group type: EXPERIMENTAL
Intervention: POSS-PCU (synthetic vascular graft)
Number of subjects: 0
Study 28347955 — intervention group
Group type: COMPARATOR
Intervention: Ovine left Subclavian artery (natural vascular graft)
Number of subjects: 0
Study 28348181 — intervention group
Group type: EXPERIMENTAL
Intervention: Rapid PTH drop
Number of subjects: 269
Study 28348181 — intervention group
Group type: EXPERIMENTAL
Intervention: Gradual PTH decrease
Number of subjects: 269
Study 28348181 — intervention group
Group type: EXPERIMENTAL
Intervention: Slow PTH decrease with high phosphate
Number of subjects: 269
Study 28348181 — intervention group
Group type: EXPERIMENTAL
Intervention: Uncontrolled SHPT
Number of subjects: 269
Study 28348181 — intervention group
Group type: EXPERIMENTAL
Intervention: KDIGO targets
Number of subjects: 269
Study 28348181 — intervention group
Group type: EXPERIMENTAL
Intervention: Cinacalcet
Number of subjects: 269
Study 28349167 — intervention group
Group type: EXPERIMENTAL
Intervention: ABT-414 (1-4 mg/kg once every 3 weeks or 1 or 1.5 mg/kg weekly for 2 out of every 3 weeks)
Number of subjects: 51
Study 28349167 — intervention group
Group type: EXPERIMENTAL
Intervention: ABT-414 (doses ≥2 mg/kg)
Number of subjects: 51
Study 28349167 — intervention group
Group type: EXPERIMENTAL
Intervention: ABT-414
Number of subjects: 51
Study 28349174 — intervention group
Group type: EXPERIMENTAL
Intervention: Intensive Lifestyle Intervention (ILI)
Number of subjects: 5145
Study 28349174 — intervention group
Group type: COMPARATOR
Intervention: Diabetes Support and Education (DSE)
Number of subjects: 5145
Study 28349262 — intervention group
Group type: EXPERIMENTAL
Intervention: β-alanine supplementation (6.4 g/day for 28 days)
Number of subjects: 23
Study 28349335 — intervention group
Group type: EXPERIMENTAL
Intervention: PEGylated asparaginase Oncaspar
Number of subjects: 1342
Study 28350250 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive behavioral workshop (N = 76)
Number of subjects: 642
Study 28350250 — intervention group
Group type: EXPERIMENTAL
Intervention: Face-to-face counseling (N = 11)
Number of subjects: 642
Study 28350250 — intervention group
Group type: EXPERIMENTAL
Intervention: Group health talk (N = 516)
Number of subjects: 642
Study 28350250 — intervention group
Group type: EXPERIMENTAL
Intervention: Telephone counseling (N = 39)
Number of subjects: 642
Study 28350250 — intervention group
Group type: EXPERIMENTAL
Intervention: Overall program (all interventions combined)
Number of subjects: 642
Study 28351230 — intervention group
Group type: EXPERIMENTAL
Intervention: Continuous monitoring of spinal cord perfusion pressure (SCPP) using a pressure probe and microdialysis catheter.
Number of subjects: 0
Study 28351230 — intervention group
Group type: EXPERIMENTAL
Intervention: Mean arterial pressure (MAP) and intraspinal pressure (ISP) measurements.
Number of subjects: 0
Study 28351230 — intervention group
Group type: EXPERIMENTAL
Intervention: Spinal pressure reactivity index (sPRx) calculation.
Number of subjects: 0
Study 28351310 — intervention group
Group type: EXPERIMENTAL
Intervention: Paclitaxel-coated, self-expanding, nitinol Stentys Stent System
Number of subjects: 70
Study 28351345 — intervention group
Group type: EXPERIMENTAL
Intervention: 3 × treatment arm (three annual rounds of MDA with azithromycin)
Number of subjects: 8
Study 28351345 — intervention group
Group type: COMPARATOR
Intervention: 1 × treatment arm (one round of MDA)
Number of subjects: 8
Study 28351351 — intervention group
Group type: EXPERIMENTAL
Intervention: Target-shooting sport intervention, practiced once a week for six months.
Number of subjects: 100
Study 28351351 — intervention group
Group type: COMPARATOR
Intervention: Waiting list control group (no intervention).
Number of subjects: 100
Study 28351355 — intervention group
Group type: EXPERIMENTAL
Intervention: Community Level Interventions for Pre-eclampsia (CLIP) intervention
Number of subjects: 32785
Study 28351355 — intervention group
Group type: EXPERIMENTAL
Intervention: Community engagement sessions and training assessments of community health workers
Number of subjects: 32785
Study 28351355 — intervention group
Group type: EXPERIMENTAL
Intervention: Qualitative data collection methods
Number of subjects: 32785
Study 28351355 — intervention group
Group type: EXPERIMENTAL
Intervention: Data analysis methods
Number of subjects: 32785
Study 28351364 — intervention group
Group type: EXPERIMENTAL
Intervention: Task-shifted cognitive-behavioral therapy (CBT) delivered by paraprofessionals
Number of subjects: 13440
Study 28351705 — intervention group
Group type: EXPERIMENTAL
Intervention: Deep cartilage layer T2 change in progressor knees
Number of subjects: 74
Study 28351705 — intervention group
Group type: COMPARATOR
Intervention: Deep cartilage layer T2 change in non-progressor knees
Number of subjects: 74
Study 28351705 — intervention group
Group type: EXPERIMENTAL
Intervention: Superficial cartilage layer T2 change in progressor knees
Number of subjects: 74
Study 28351705 — intervention group
Group type: COMPARATOR
Intervention: Superficial cartilage layer T2 change in non-progressor knees
Number of subjects: 74
Study 28351705 — intervention group
Group type: EXPERIMENTAL
Intervention: Baseline medial femorotibial cartilage T2 in progressor knees (superficial layer)
Number of subjects: 74
Study 28351705 — intervention group
Group type: COMPARATOR
Intervention: Baseline medial femorotibial cartilage T2 in non-progressor knees (superficial layer)
Number of subjects: 74
Study 28351705 — intervention group
Group type: EXPERIMENTAL
Intervention: Baseline medial femorotibial cartilage T2 in progressor knees (deep layer)
Number of subjects: 74
Study 28351705 — intervention group
Group type: COMPARATOR
Intervention: Baseline medial femorotibial cartilage T2 in non-progressor knees (deep layer)
Number of subjects: 74
Study 28351831 — intervention group
Group type: EXPERIMENTAL
Intervention: Chemotherapy + Selective Internal Radiation Therapy (SIRT) using yttrium-90 resin microspheres
Number of subjects: 0
Study 28351831 — intervention group
Group type: EXPERIMENTAL
Intervention: FOLFOX6m + SIR-Spheres microspheres
Number of subjects: 0
Study 28351831 — intervention group
Group type: COMPARATOR
Intervention: FOLFOX6m alone
Number of subjects: 0
Study 28351831 — intervention group
Group type: EXPERIMENTAL
Intervention: Chemotherapy + SIRT
Number of subjects: 0
Study 28351842 — intervention group
Group type: EXPERIMENTAL
Intervention: Intracoronary infusion of autologous bone marrow-derived mononuclear cells (BMCs)
Number of subjects: 157
Study 28351842 — intervention group
Group type: EXPERIMENTAL
Intervention: Baseline hs-TnT levels
Number of subjects: 157
Study 28351901 — intervention group
Group type: EXPERIMENTAL
Intervention: Patients with late gadolinium enhancement (LGE)
Number of subjects: 399
Study 28351901 — intervention group
Group type: COMPARATOR
Intervention: Patients without late gadolinium enhancement (LGE)
Number of subjects: 399
Study 28353191 — intervention group
Group type: EXPERIMENTAL
Intervention: Certolizumab pegol (CZP) 400 mg every 4 weeks (Q4W) monotherapy
Number of subjects: 427
Study 28353191 — intervention group
Group type: EXPERIMENTAL
Intervention: Certolizumab pegol (CZP) 400 mg every 4 weeks (Q4W) in combination with methotrexate (MTX)
Number of subjects: 427
Study 28355434 — intervention group
Group type: EXPERIMENTAL
Intervention: Apixaban therapy
Number of subjects: 3417
Study 28355434 — intervention group
Group type: COMPARATOR
Intervention: Warfarin therapy
Number of subjects: 3417
Study 28356179 — intervention group
Group type: EXPERIMENTAL
Intervention: Dexmedetomidine (DEX) sedation at a dose of 2 μg/kg/h
Number of subjects: 50
Study 28356179 — intervention group
Group type: COMPARATOR
Intervention: Natural sleep
Number of subjects: 50
Study 28356182 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-level continuous positive airway pressure (CPAP) at 2, 4, or 6 cm H2O
Number of subjects: 0
Study 28356182 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-level CPAP
Number of subjects: 0
Study 28356241 — intervention group
Group type: EXPERIMENTAL
Intervention: 3D VR intervention using Samsung Gear Oculus VR headset
Number of subjects: 100
Study 28356241 — intervention group
Group type: COMPARATOR
Intervention: 2D distraction video on a 14-inch bedside screen (Control)
Number of subjects: 100
Study 28356275 — intervention group
Group type: EXPERIMENTAL
Intervention: Konjac glucomannan, a viscous soluble fiber, dosage and duration not specified
Number of subjects: 0
Study 28356275 — intervention group
Group type: COMPARATOR
Intervention: Control group not specified
Number of subjects: 0
Study 28356278 — intervention group
Group type: EXPERIMENTAL
Intervention: Not available
Number of subjects: 0
Study 28356282 — intervention group
Group type: EXPERIMENTAL
Intervention: Ticagrelor 180 mg loading dose (LD)
Number of subjects: 2
Study 28356282 — intervention group
Group type: COMPARATOR
Intervention: Clopidogrel 600 mg loading dose (LD)
Number of subjects: 2
Study 28356426 — intervention group
Group type: EXPERIMENTAL
Intervention: Whole-grain intake as reflected by dietary records and biomarkers
Number of subjects: 0
Study 28356432 — intervention group
Group type: EXPERIMENTAL
Intervention: Diet with inflammatory potential
Number of subjects: 0
Study 28356432 — intervention group
Group type: COMPARATOR
Intervention: Control group not specified
Number of subjects: 0
Study 28356440 — intervention group
Group type: EXPERIMENTAL
Intervention: Revascularization for coronary artery stenosis with a low FFR (≤0.75)
Number of subjects: 5846
Study 28356440 — intervention group
Group type: COMPARATOR
Intervention: Deferred lesions with FFR measurement
Number of subjects: 5846
Study 28356440 — intervention group
Group type: COMPARATOR
Intervention: Medical treatment for stenosis with a high FFR (≥0.76)
Number of subjects: 5846
Study 28357679 — intervention group
Group type: EXPERIMENTAL
Intervention: Veterans RAND 12-Item Health Survey (VR-12) - Physical Component Summary (PCS)
Number of subjects: 7902
Study 28357679 — intervention group
Group type: EXPERIMENTAL
Intervention: Veterans RAND 12-Item Health Survey (VR-12) - Mental Component Summary (MCS)
Number of subjects: 7902
Study 28357679 — intervention group
Group type: EXPERIMENTAL
Intervention: Global assessment measure for quality of life
Number of subjects: 7902
Study 28357679 — intervention group
Group type: EXPERIMENTAL
Intervention: Overall VR-12 score
Number of subjects: 7902
Study 28357679 — intervention group
Group type: EXPERIMENTAL
Intervention: Orthopedic surgery
Number of subjects: 7902
Study 28357679 — intervention group
Group type: EXPERIMENTAL
Intervention: Gastrointestinal/hepatobiliary or urologic surgery
Number of subjects: 7902
Study 28357727 — intervention group
Group type: EXPERIMENTAL
Intervention: BEZ235 (dactolisib) at doses of 200, 400, and 800 mg daily along with everolimus at 2.5 mg daily in 28-day cycles
Number of subjects: 19
Study 28357772 — intervention group
Group type: EXPERIMENTAL
Intervention: Once-daily injected GLP1 agonist lixisenatide (Lixi) and basal insulin analogue glargine (iGlar)
Number of subjects: 9
Study 28358734 — intervention group
Group type: EXPERIMENTAL
Intervention: Antiretroviral therapy (ART)
Number of subjects: 19
Study 28359201 — intervention group
Group type: EXPERIMENTAL
Intervention: Adjunctive Vagus Nerve Stimulation (VNS)
Number of subjects: 795
Study 28359201 — intervention group
Group type: COMPARATOR
Intervention: Treatment as Usual
Number of subjects: 795
Study 28359318 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined targeted therapy bevacizumab and erlotinib (BE)
Number of subjects: 43
Study 28359411 — intervention group
Group type: EXPERIMENTAL
Intervention: Spironolactone
Number of subjects: 687
Study 28359411 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 687
Study 28360015 — intervention group
Group type: EXPERIMENTAL
Intervention: Etirinotecan pegol (145 mg/m2)
Number of subjects: 733
Study 28360015 — intervention group
Group type: COMPARATOR
Intervention: Treatment of physician's choice (TPC)
Number of subjects: 733
Study 28360015 — intervention group
Group type: EXPERIMENTAL
Intervention: Etirinotecan pegol
Number of subjects: 733
Study 28360015 — intervention group
Group type: EXPERIMENTAL
Intervention: Both treatment arms
Number of subjects: 733
Study 28360208 — intervention group
Group type: EXPERIMENTAL
Intervention: Immune checkpoint inhibitor therapy
Number of subjects: 0
Study 28360208 — intervention group
Group type: COMPARATOR
Intervention: Control group not specified
Number of subjects: 0
Study 28360242 — intervention group
Group type: EXPERIMENTAL
Intervention: Northern Shanghai Risk Score calculation based on CV risk factors and TODs
Number of subjects: 0
Study 28360242 — intervention group
Group type: EXPERIMENTAL
Intervention: Clinical examination, anthropometric measurement, and questionnaire
Number of subjects: 0
Study 28360242 — intervention group
Group type: EXPERIMENTAL
Intervention: Follow-up assessments every 2 years
Number of subjects: 0
Study 28360250 — intervention group
Group type: EXPERIMENTAL
Intervention: Brussels Infant and Toddler Stool Scale (BITSS)
Number of subjects: 0
Study 28360259 — intervention group
Group type: EXPERIMENTAL
Intervention: Patients with HFpEF (n=22)
Number of subjects: 34
Study 28360259 — intervention group
Group type: COMPARATOR
Intervention: Patients without HFpEF (n=12)
Number of subjects: 34
Study 28360853 — intervention group
Group type: EXPERIMENTAL
Intervention: Dance intervention
Number of subjects: 174
Study 28360853 — intervention group
Group type: COMPARATOR
Intervention: Walking intervention
Number of subjects: 174
Study 28360853 — intervention group
Group type: COMPARATOR
Intervention: Walking + Nutrition intervention
Number of subjects: 174
Study 28360853 — intervention group
Group type: COMPARATOR
Intervention: Active Control (stretching and toning)
Number of subjects: 174
Study 28361390 — intervention group
Group type: EXPERIMENTAL
Intervention: Magnesium sulfate pretreatment
Number of subjects: 26
Study 28361390 — intervention group
Group type: COMPARATOR
Intervention: Oxytocin 10
Number of subjects: 26